Mont-Saint-Guibert, Belgium, December 15, 2023, 10:01 pm CET; regulated information – Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces that 6,500,000 shares of CFIP CLYD (UK) Limited benefit from a double voting right as of December 8, 2023. As a result, the Company’s total number of voting rights is now 50,296,947.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on December 8, 2023, following the Double Voting Right:
| Total amount of share capital (EUR) | 88,378,224.25 |
| Total Number of shares with single voting rights | 32,560,197 |
| Total Number of shares with double voting rights | 8,868,375 |
| Total Number of Shares | 41,428,572 |
| Total of voting rights | 50,296,947 |
| Total number of attributed warrants | 3,038,871 |
| Total number of shares with voting rights that could be created following the exercise of the attributed warrants | 3,038,871 |
| Total number of diluted shares (Outstanding shares + Warrants) | 44,457,443 |
| Total number of diluted voting rights | 53,335,818 |
Contact person for regulated information (financial, transparency)
By law, any transparency declaration must be sent to our Company by email to the attention of Michel Lussier, Chief Executive Officer ad interim (CEO ad interim): investors@celyad.com.
Further questions about the content of this release can be sent to investors@celyad.com.
